{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:06:35Z","timestamp":1793149595238,"version":"4.5.0"},"reference-count":57,"publisher":"American Association for Cancer Research (AACR)","issue":"8","funder":[{"name":"NHS Innovation Accelerator"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Global interest in genetic testing for cancer susceptibility genes (CSG) has surged with falling costs, increasing awareness, and celebrity endorsement. Current access to genetic testing is based on clinical criteria\/risk model assessment which uses family history as a surrogate. However, this approach is fraught with inequality, massive underutilization, and misses 50% CSG carriers. This reflects huge missed opportunities for precision prevention. Early CSG identification enables uptake of risk-reducing strategies in unaffected individuals to reduce cancer risk. Population-based genetic testing (PGT) can overcome limitations of clinical criteria\/family history\u2013based testing. Jewish population studies show population-based BRCA testing is feasible, acceptable, has high satisfaction, does not harm psychologic well-being\/quality of life, and is extremely cost-effective, arguing for changing paradigm to PGT in the Jewish population. Innovative approaches for delivering pretest information\/education are needed to facilitate informed decision-making for PGT. Different health systems will need context-specific implementation strategies and management pathways, while maintaining principles of population screening. Data on general population PGT are beginning to emerge, prompting evaluation of wider implementation. Sophisticated risk prediction models incorporating genetic and nongenetic data are being used to stratify populations for ovarian cancer and breast cancer risk and risk-adapted screening\/prevention. PGT is potentially cost-effective for panel testing of breast and ovarian CSGs and for risk-adapted breast cancer screening. Further research\/implementation studies evaluating the impact, clinical efficacy, psychologic and socio\u2013ethical consequences, and cost-effectiveness of PGT are needed.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-20-0002","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T19:08:10Z","timestamp":1589483290000},"page":"643-648","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Population-based Genetic Testing for Precision Prevention"],"prefix":"10.1158","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-4964","authenticated-orcid":false,"given":"Olivia","family":"Evans","sequence":"first","affiliation":[{"name":"1Wolfson Institute of Preventative Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London, United Kingdom."},{"name":"2Department of Gynaecological Oncology, St Bartholomew's Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-5057","authenticated-orcid":false,"given":"Ranjit","family":"Manchanda","sequence":"additional","affiliation":[{"name":"1Wolfson Institute of Preventative Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London, United Kingdom."},{"name":"2Department of Gynaecological Oncology, St Bartholomew's Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"2022060815423329900_bib1","doi-asserted-by":"crossref","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"key":"2022060815423329900_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"key":"2022060815423329900_bib3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2022060815423329900_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022060815423329900_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"},{"key":"2022060815423329900_bib6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2022060815423329900_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060815423329900_bib9","volume-title":"Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations","author":"NHS England","year":"2015"},{"key":"2022060815423329900_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2017.06.002","article-title":"Multi-disciplinary summit on genetics services for women with gynecologic cancers: a Society of Gynecologic Oncology White Paper","volume":"146","author":"Randall","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2022060815423329900_bib11","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jmedgenet-2017-105195","article-title":"Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population","volume":"55","author":"Manchanda","year":"2018","journal-title":"J Med Genet"},{"key":"2022060815423329900_bib13","volume-title":"Principles and practice of screening for disease","author":"Wilson","year":"1968"},{"key":"2022060815423329900_bib14","article-title":"Criteria for appraising the viability, effectiveness and appropriateness of a screening programme","author":"UK"},{"key":"2022060815423329900_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMra013182","article-title":"Population screening in the age of genomic medicine","volume":"348","author":"Khoury","year":"2003","journal-title":"N Engl J Med"},{"key":"2022060815423329900_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2471\/BLT.07.050112","article-title":"Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years","volume":"86","author":"Andermann","year":"2008","journal-title":"Bull World Health Organ"},{"key":"2022060815423329900_bib17","volume-title":"ACCE model process for evaluating genetic tests","year":"2010"},{"key":"2022060815423329900_bib18","volume-title":"Moving beyond ACCE: an expanded framework for genetic test evaluation","author":"Burke","year":"2007"},{"key":"2022060815423329900_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/1471-0528.15905","article-title":"Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes","volume":"127","author":"Manchanda","year":"2020","journal-title":"BJOG"},{"key":"2022060815423329900_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/1471-0528.15654","article-title":"Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study","volume":"126","author":"Manchanda","year":"2019","journal-title":"BJOG"},{"key":"2022060815423329900_bib21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jmedgenet-2015-103740","article-title":"Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1\/2 mutations","volume":"53","author":"Manchanda","year":"2016","journal-title":"J Med Genet"},{"key":"2022060815423329900_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2022060815423329900_bib23","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060815423329900_bib24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/gim.2016.175","article-title":"Population screening for BRCA1\/BRCA2 mutations: lessons from qualitative analysis of the screening experience","volume":"19","author":"Lieberman","year":"2017","journal-title":"Genet Med"},{"key":"2022060815423329900_bib25","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/gim.2018.26","article-title":"Familial communication and cascade testing among relatives of BRCA population screening participants","volume":"20","author":"Lieberman","year":"2018","journal-title":"Genet Med"},{"key":"2022060815423329900_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1399-0004.2010.01499.x","article-title":"Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2","volume":"78","author":"Metcalfe","year":"2010","journal-title":"Clin Genet"},{"key":"2022060815423329900_bib27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib28","article-title":"Online BRCA1\/2 screening in the Australian Jewish community: a qualitative study","author":"Yuen","year":"2019","journal-title":"J Community Genet"},{"key":"2022060815423329900_bib29","volume-title":"BRCA founder outreach study","author":"BFOR"},{"key":"2022060815423329900_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10549-011-1941-0","article-title":"Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening","volume":"133","author":"Metcalfe","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022060815423329900_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2022060815423329900_bib32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ajog.2017.06.038","article-title":"Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry","volume":"217","author":"Manchanda","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2022060815423329900_bib33","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jama.2019.8430","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"2022060815423329900_bib34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020","volume":"18","author":"Daly","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2022060815423329900_bib35","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2003.03.189","article-title":"American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/gim.2016.182","article-title":"Population screening for BRCA1\/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral","volume":"19","author":"Lieberman","year":"2017","journal-title":"Genet Med"},{"key":"2022060815423329900_bib37","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2015.65.9557","article-title":"Randomized noninferiority trial of telephone delivery of BRCA1\/2 genetic counseling compared with in-person counseling: 1-year follow-up","volume":"34","author":"Kinney","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib39","volume-title":"Predicting risk of ovarian malignancy improved screening and early detection feasibility study ISRCTN Registry: ISRCTN54246466","author":"Manchanda","year":"2017"},{"key":"2022060815423329900_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"2022060815423329900_bib41","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022060815423329900_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/gepi.1022","article-title":"Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study","volume":"21","author":"Chatterjee","year":"2001","journal-title":"Genet Epidemiol"},{"key":"2022060815423329900_bib43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.0006-341X.2001.00245.x","article-title":"A marginal likelihood approach for estimating penetrance from kin-cohort designs","volume":"57","author":"Chatterjee","year":"2001","journal-title":"Biometrics"},{"key":"2022060815423329900_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"key":"2022060815423329900_bib45","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.mayocp.2018.06.026","article-title":"The return of actionable variants empirical (RAVE) study, a Mayo Clinic genomic medicine implementation study: design and initial results","volume":"93","author":"Kullo","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2022060815423329900_bib46","doi-asserted-by":"crossref","first-page":"e182140","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2022060815423329900_bib47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","article-title":"Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility","volume":"21","author":"Rowley","year":"2019","journal-title":"Genet Med"},{"key":"2022060815423329900_bib48","doi-asserted-by":"crossref","first-page":"k1687","DOI":"10.1136\/bmj.k1687","article-title":"The 100 000 Genomes Project: bringing whole genome sequencing to the NHS","volume":"361","author":"Turnbull","year":"2018","journal-title":"BMJ"},{"key":"2022060815423329900_bib49","doi-asserted-by":"crossref","first-page":"e017675","DOI":"10.1136\/bmjopen-2017-017675","article-title":"Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK","volume":"7","author":"Meisel","year":"2017","journal-title":"BMJ Open"},{"key":"2022060815423329900_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12905-016-0325-3","article-title":"Genetic testing and personalized ovarian cancer screening: a survey of public attitudes","volume":"16","author":"Meisel","year":"2016","journal-title":"BMC Womens Health"},{"key":"2022060815423329900_bib51","doi-asserted-by":"publisher","DOI":"10.1186\/ISRCTN25173360","volume-title":"Preventing ovarian cancer through early excision of tubes and late ovarian removal (PROTECTOR)","author":"Manchanda","year":"2019"},{"key":"2022060815423329900_bib52","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women","volume":"110","author":"Manchanda","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2022060815423329900_bib53","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2018.1901","article-title":"Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model","volume":"4","author":"Pashayan","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022060815423329900_bib54","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1055-9965.EPI-18-0810","article-title":"Performance of single-nucleotide polymorphisms in breast cancer risk prediction models: a systematic review and meta-analysis","volume":"28","author":"Fung","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060815423329900_bib55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fgene.2019.00267","article-title":"Machine learning SNP based prediction for precision medicine","volume":"10","author":"Schierding","year":"2019","journal-title":"Front Genet"},{"key":"2022060815423329900_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/GIM.0b013e31815699d0","article-title":"The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?","volume":"9","author":"Khoury","year":"2007","journal-title":"Genet Med"},{"key":"2022060815423329900_bib57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/GIM.0b013e3181b13a6c","article-title":"The scientific foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop","volume":"11","author":"Khoury","year":"2009","journal-title":"Genet Med"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/13\/8\/643\/2242369\/643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/13\/8\/643\/2242369\/643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T16:12:31Z","timestamp":1654704751000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/13\/8\/643\/47334\/Population-based-Genetic-Testing-for-Precision"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,4]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-20-0002","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}